Constant Therapeutics

Constant Therapeutics is a private biotech leveraging the protective and regenerative pathways of the Alternative Renin-Angiotensin System (RAS) to develop therapies for rare and severe disorders. The company's core platform involves activating the Mas and MrgD receptors to counteract the harmful effects of the classical RAS, with applications in cardiology, neurology, and dermatology. Its lead asset, TXA127, is currently in Phase 2 trials for Duchenne Muscular Dystrophy-associated cardiomyopathy and ischemic stroke recovery, positioning the company at a critical clinical inflection point. The firm operates as a lean, pre-revenue entity targeting high-value, underserved markets.

Development of peptide and small molecule drugs targeting the protective Alternative Renin-Angiotensin System (RAS) pathway, specifically agonists of the Mas and MrgD receptors, to counteract the harmful effects of the classical RAS and promote anti-fibrotic, anti-inflammatory, and regenerative effects.

Competition varies by indication. In DMD, it faces established cardioprotective standard care and emerging genetic therapies. In stroke recovery, it is a pioneer with few direct pharmacological competitors. In EB, it would compete against advanced gene and cell therapies. Broader competition includes other firms targeting the Mas receptor pathway across different disease areas.